Working... Menu

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus (PORTAL 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00964574
Recruitment Status : Completed
First Posted : August 25, 2009
Last Update Posted : July 17, 2012
Information provided by (Responsible Party):

Brief Summary:

Primary Objective:

To evaluate the efficacy and the safety of insulin glulisine in type I Diabetes Melittus (DM) patients

Secondary Objective:

To evaluate the insulin glulisine doses To assess the patient satisfaction

Condition or disease Intervention/treatment Phase
Diabetes Mellitus, Type 1 Drug: INSULIN GLULISINE (HMR1964) Drug: INSULIN GLARGINE Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 68 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicentre, Open, Non-randomised Controlled Phase IV Clinical Trial of Efficacy and Safety for Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine
Study Start Date : July 2009
Actual Primary Completion Date : July 2010
Actual Study Completion Date : July 2010

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Arm Intervention/treatment
Experimental: APIDRA + LANTUS basal
The 2 first weeks, patients will receive subcutaneous injection of Insulin Glulisine and Insulin Glargine once daily in hospital. The rest of the treatement is to be take at home until week 12

Pharmaceutical form:

APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet

Route of administration:

3-4 subcutaneous injections per day


Pharmaceutical form:

LANTUS 100U/ml solution for injection in cartridge

Route of administration:

Once daily subcutaneous injection in the evening

Primary Outcome Measures :
  1. Mean change in Glycosylated haemoglobin (HbA1c) [ Time Frame: Week 12 ]

Secondary Outcome Measures :
  1. Mean Glycosylated haemoglobin (HbA1c) [ Time Frame: Week 12 ]
  2. Mean Fasting Blood Glucose and mean Post Prandial Glycemia [ Time Frame: Week 12 ]
  3. Number of documented symptomatic hypoglycaemic episodes [ Time Frame: From week 0 to week 12 ]
  4. Mean dose and mean dose change of insulin glulisine, basal glulisine and total insulin from baseline [ Time Frame: week 12 ]
  5. Mean change of Fasting Blood Glucose and Post Prandial Glycemia [ Time Frame: From week 0 to week 12 ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients with type 1 diabetes mellitus who need insulin basal+ bolus regimen
  • 6.5 <=HbA1c <= 11% at visit 1
  • BMI <35 kg/m²
  • Provision of signed and dated informed consent prior to any study procedures
  • Ability and willingness to complete study diaries and questionnaires
  • Demonstrated ability to use the self-glucose-monitoring device, and to self-inject insulin
  • A negative pregnancy test for all females of childbearing potential.

Exclusion criteria:

  • Hypersensitivity to insulin Glulisine, insulin Glargine or one of their excipients
  • Pregnant women
  • Active proliferative diabetic retinopathy
  • Impaired hepatic or renal function

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00964574

Layout table for location information
Sanofi-Aventis Administrative Office
Minsk, Belarus
Sponsors and Collaborators
Layout table for investigator information
Study Director: Natallia Zhyhaila Sanofi

Layout table for additonal information
Responsible Party: Sanofi Identifier: NCT00964574     History of Changes
Other Study ID Numbers: APIDR_L_02483
First Posted: August 25, 2009    Key Record Dates
Last Update Posted: July 17, 2012
Last Verified: July 2012

Additional relevant MeSH terms:
Layout table for MeSH terms
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases
Insulin, Globin Zinc
Insulin Glargine
Insulin glulisine
Hypoglycemic Agents
Physiological Effects of Drugs